ROTATEQ 2040000 UNIT
HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G4 : 2040000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G2 : 2840000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE P1(8) : 2290000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G1 : 2210000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G3 : 2220000 UNIT · DIN 02284413 · MERCK CANADA INC
Health Canada status: MARKETED
What is ROTATEQ?
ROTATEQ 2040000 UNIT contains HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G4 : 2040000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G2 : 2840000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE P1(8) : 2290000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G1 : 2210000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G3 : 2220000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02284413, held by MERCK CANADA INC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Oct-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROTATEQ used for?
RotaTeq® (rotavirus vaccine, live, oral, pentavalent) is indicated for the prevention of rotavirus gastroenteritis caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1A[8], when administered to infants 6 weeks through 32 weeks of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02284413 |
|---|---|
| Brand name | ROTATEQ |
| Generic / active ingredient | HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G4 : 2040000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G2 : 2840000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE P1(8) : 2290000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G1 : 2210000 UNIT HUMAN-BOVINE ROTAVIRUS REASSORTANT TYPE G3 : 2220000 UNIT |
| Manufacturer | MERCK CANADA INC |
| Strength | 2040000 UNIT |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Schedule D |
| ATC code | J07BH02 ROTA VIRUS, PENTAVALENT, LIVE, REASSORTED |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Oct-2006 |
How is it stored and handled?
null
How is it supplied?
Packages of 10 single-dose tubes.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.